Proton Radiation—Yea or Nay?
Controversy over the value of proton beam radiation continues to harass clinicians as the therapy emerges to be extremely useful in some, but not all, cancers. Additionally, payers sometimes refuse to cover treatment costs due to lack of evidence of efficacy.
Marketplaces Will Have 25% More Insurers in 2015
The health insurance Marketplace will have 77 new insurers offering coverage in 2015, according to a report released by HHS. Overall, there will be a net 25% increase in the number of insurers that consumers will be able to choose from.
NIH Seeks Gender Equality in Research Studies
The National Institutes of Health announced disbursement of more than $10 million in research funding to researchers studying various healthcare issues. The objective of this additional funding is to avoid gender bias and seek equal representation of female subjects.
Number of Medicare Part D Drug Plans Down in 2015
Driven by a consolidation of offerings, the number of Part D prescription drug plans will decrease by 14% in 2015. While monthly premiums will decrease overall by 2%, there will be large premium variations.
Dr Fridsma Leaves ONC to Be President and CEO of AMIA
Doug Fridsma, MD, PhD, FACP, FACMI, is leaving his position as the chief science officer for the Office of the National Coordinator for Health Information Technology to become the president and CEO of the American Medical Informatics Association.
Introducing: American Association for Physician Leadership
In response to the growing recognition that physician leadership is essential to the successful transformation of healthcare, the American College of Physician Executives is becoming the American Association for Physician Leadership.
Consumers Find ACA Insurance Plans Affordable
Although a majority of adults with health insurance purchased through the Affordable Care Act’s marketplace said they find it easy to afford the care they need, the number of people still enrolled has dipped to 7.3 million, according to recent numbers.
Gilead's Zydelig Receives EU Nod for CLL and FL
The approval in CLL is supported primarily by data from a randomized, placebo-controlled phase 3 trial in combination with rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The approval in FL, is supported by data from a single-arm phase 2 study (Study 101-09) of Zydelig monotherapy in 125 iNHL patients refractory to rituximab and alkylating-agent-containing chemotherapy.
UK's NICE Wins Drug Price War With GSK
Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.
Novo's Long-Acting Insulin, Tresiba, Safe and Effective
Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.